Status:

COMPLETED

Fat Cell Size in Insulin Resistance

Lead Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Obesity

Eligibility:

All Genders

18-65 years

Brief Summary

This study, conducted at Stanford University in Palo Alto, California, will examine how insulin metabolism and cardiovascular risk are altered in response to weight loss. Insulin is a natural hormone ...

Detailed Description

Little is known about the turnover of adipose cells in the fat depots of normal animals and human subjects. However, microarray analysis of adipose cell gene expression in high risk insulin-resistant ...

Eligibility Criteria

Inclusion

  • INCLUSION AND EXCLUSION CRITERIA:
  • Without regard to gender, race, or socioeconomic status, all subjects will be adult men and women. The racial/ethnic composition of the study population will be reflective of the communities surrounding Stanford University. Subjects will be recruited through placement of advertisements in local newspapers, but no subjects will be seen at NIH.

Exclusion

    Key Trial Info

    Start Date :

    September 4 2003

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    August 10 2020

    Estimated Enrollment :

    782 Patients enrolled

    Trial Details

    Trial ID

    NCT00341406

    Start Date

    September 4 2003

    End Date

    August 10 2020

    Last Update

    August 17 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK), 9000

    Bethesda, Maryland, United States, 20892